Figure S5. Flow diagram of participants in the cross-sectional study according a) to the three-gene methylation classifier and cytology results and b) to the combined three-gene methylation/cytology classifier. Abbreviations: R-PFBC, recurrent patients in follow-up for bladder cancer; NR-PFBC, non-recurrent patients in follow-up for bladder cancer; Cytol, cytology; NA, non-available; Test, combined three-gene methylation/cytology classifier. (PPTX 85Â kb
Detailed frequency of DNAm of BRCA1, MGMT, and ERCC1 across cancer entities and corresponding normal...
Figure S2. Validation of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 as biomarkers for BC diagnosis and ...
Figure S1. Concentrations of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 and their diagnostic performanc...
Figure S1. Flowchart of the entire study. A total of seven hypermethylated genes, differentially exp...
Figure S4. Sensitivity, negative and positive predictive values of urine cytology, the three-gene me...
Figure S3. Representative pyrograms showing gene methylation patterns in DNA urine samples from a bl...
Figure S6. DNA methylation profiles for bladder cancer and control tissue samples for the three-gene...
Table S2. Percentage of methylation for each CpG dinucleotide in the seven selected genes in control...
Table S1. Results of modeling using continuous and binary methylation levels. Table S2. the range of...
The demographic and clinical characteristics of training group. Table S1. The demographic and clinic...
Table S1. Primer sequences for β-Actin, miR-34b/c, and miR-193b (panel #1). Table S2. Scorpion prime...
Table S3. List of CpG islands included in the biomarker panel. Table S4. List of primers and probes....
Table S1. Correlations. Spearman’s rank correlations for the PMR values of each biomarker, ProCUrE, ...
Figure S2. Box-plots of panel #1 (miR-34b/c, miR-193b) and panel #2 (APC, RARβ2) promoter methylatio...
Eggerâs funnel plot of the publication bias test for CDH13 methylation. (DOCX 21Â kb
Detailed frequency of DNAm of BRCA1, MGMT, and ERCC1 across cancer entities and corresponding normal...
Figure S2. Validation of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 as biomarkers for BC diagnosis and ...
Figure S1. Concentrations of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 and their diagnostic performanc...
Figure S1. Flowchart of the entire study. A total of seven hypermethylated genes, differentially exp...
Figure S4. Sensitivity, negative and positive predictive values of urine cytology, the three-gene me...
Figure S3. Representative pyrograms showing gene methylation patterns in DNA urine samples from a bl...
Figure S6. DNA methylation profiles for bladder cancer and control tissue samples for the three-gene...
Table S2. Percentage of methylation for each CpG dinucleotide in the seven selected genes in control...
Table S1. Results of modeling using continuous and binary methylation levels. Table S2. the range of...
The demographic and clinical characteristics of training group. Table S1. The demographic and clinic...
Table S1. Primer sequences for β-Actin, miR-34b/c, and miR-193b (panel #1). Table S2. Scorpion prime...
Table S3. List of CpG islands included in the biomarker panel. Table S4. List of primers and probes....
Table S1. Correlations. Spearman’s rank correlations for the PMR values of each biomarker, ProCUrE, ...
Figure S2. Box-plots of panel #1 (miR-34b/c, miR-193b) and panel #2 (APC, RARβ2) promoter methylatio...
Eggerâs funnel plot of the publication bias test for CDH13 methylation. (DOCX 21Â kb
Detailed frequency of DNAm of BRCA1, MGMT, and ERCC1 across cancer entities and corresponding normal...
Figure S2. Validation of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 as biomarkers for BC diagnosis and ...
Figure S1. Concentrations of UE-derived MALAT1, PCAT-1 and SPRY4-IT1 and their diagnostic performanc...